The Max Foundation
Accelerating health equity, one patient at a time.
Programs and results
What we aim to solve
By 2030, the World Health Organization projects that the number of new cancer patients diagnosed each year will double to more than 23 million worldwide. But the vast majority of those – 7 out of 10 – will be in low- and middle-income countries (LMICs) where optimal treatment and care is a rarity. For the people in these countries, disproportionate burden and inadequate resources will combine to devastating effect unless new and innovative solutions are developed to bridge the gaps in the availability of cancer treatments.
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Max Access Solutions
Max Access Solutions is The Max Foundation’s operational program through which humanitarian donations of oncology products are channeled to patients in need. Max Access Solutions is meant to be a bridge for access to treatment specifically within low- and middle-income countries where the burden of disease is high and local government access programs may not be currently feasible. Within Max Access Solutions, partner pharmaceutical companies donate product to The Max Foundation, who channels product to patients in need through their treating physician and within the scope of its collaboration agreements. The Max Foundation serves approximately 34,000 patients/year in over 75 countries through a network of qualified medical institutions and physicians.
Where we work
External reviews
Videos
Our results
How does this organization measure their results? It's a hard question but an important one.
Number of chronically ill patients served
This metric is no longer tracked.Totals By Year
Population(s) Served
Children and youth, Adults, Economically disadvantaged people
Related Program
Max Access Solutions
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Number of free daily doses of medicine given
This metric is no longer tracked.Totals By Year
Population(s) Served
Children and youth, Adults, Economically disadvantaged people
Related Program
Max Access Solutions
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Context Notes
Dosage refers to the daily required dose for optimal patient well-being in line with standard treatment guidelines for each disease.
Number of low- and middle-income countries where we are serving cancer patients.
This metric is no longer tracked.Totals By Year
Population(s) Served
Children and youth, Adults, Economically disadvantaged people
Related Program
Max Access Solutions
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Our Sustainable Development Goals
Learn more about Sustainable Development Goals.
Goals & Strategy
Reports and documents
Download strategic planLearn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
The Max Foundations aims to decrease premature mortality from cancer in under-resourced regions of the world by increasing access to treatment, care, and support.
Our aim directly aligns with one of the key Sustainable Development Goals set by the United Nations in September of 2015: “By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.”
What are the organization's key strategies for making this happen?
Achieving our aim means developing innovative treatment access solutions so people diagnosed with cancer in LMICs can gain access to any approved treatment indicated for their disease (i.e. treatments already available to patients in high-income countries) as prescribed by their treating physician. Max Access Solutions, our unique patient-centered model, does exactly that.
Max Access Solutions provides a long-term bridge to treatment for individually identified patients who live in countries where the prescribed cancer medicine(s) are not locally available. The model focuses on the patient and their needs across the disease spectrum, harnessing the power of multisector collaborations including drug manufacturers, international distributors, diagnostics companies, Ministries of Health, MOH hospitals, cancer centers and other public institutions in recipient countries, local NGOs and patient organizations, as well as a cancer research center in the United States.
Our Max Access Solutions model is innovative among donation programs because products are only procured following identification of individual patients in need, avoiding historical concerns of product dumping, drug diversion, and expire of unused drug. It is innovative among cancer control initiatives because it views access to treatment as its core goal from which long-term sustainability will follow.
What are the organization's capabilities for doing this?
The Max Foundation’s treatment access innovations began in 2001, when we co-developed the Glivec® International Patient Assistance Program (GIPAP) with Novartis. We’ve administered GIPAP ever since and it has become the most successful cancer-treatment access program in history, providing medicine to more than 70,000 people. Today, via our flagship program, Max Access Solutions, we offer 11 different cancer and other critical illness medications in partnership with five different pharmaceutical companies, and distribute those medicines to over 383 hospital and clinics in 73+ countries. Max Access Solutions represents a novel approach to humanitarian access to treatment – an international NGO acts as the clearinghouse for products sourced from multiple manufacturers and channels them to validated treatment centers for individual patients. Our model also provides support with patient tracking, planning and forecasting, diagnostic capabilities and reagents, provider training, and patient education and adherence support.
What have they accomplished so far and what's next?
Since its launch in 2016, Max Access Solutions has already provided access to all targeted cancer medications approved for chronic myeloid leukemia (CML) in some of the world’s lowest-income economies, and have expanded our treatment portfolio to include other critical illnesses. We are currently supplying more than 30,000 patients in LMICs with about 10,000,000 daily doses of medication each year. Our portfolio of diseases now includes:
Chronic myeloid leukemia (CML)
Non-small cell lung cancer (NSCLC)
Dermatofibrosarcoma protuberans (DFSP)
Gastrointestinal stromal tumor (GIST)
Hypereosinophilic syndrome/Chronic eosinophilic leukemia (HES/CEL)
Myelodysplastic/myeloproliferative diseases (MDS/MPD)
Systemic mastocytosis (SM)
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Renal cell carcinoma (RCC)
Pancreatic neuroendocrine tumors (pNET)
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
The Max Foundation
Board of directorsas of 11/01/2023
Paula Boultbee
Jerald Radich
Fred Hutchinson Cancer Research Center
Paula Boultbee
Susan Jerian
ONCORD, Inc.
Mika Matsuzaki
Johns Hopkins Bloomberg School of Public Health
Curt Malloy
Cancer Research and Biostatistics (CRAB)
Graciela Mabel Woloj Rothstein
MW Consulting
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? No -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? No
Organizational demographics
Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.
Leadership
The organization's leader identifies as:
Race & ethnicity
No data
Gender identity
Transgender Identity
Sexual orientation
No data
Disability
No data
Equity strategies
Last updated: 04/05/2022GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more
- We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
- We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
- We have community representation at the board level, either on the board itself or through a community advisory board.
- We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.